Abstract:In the majority of patients multiple sclerosis starts with a relapsing remitting course (RRMS), which may at later times transform into secondary progressive disease (SPMS). In a minority of patients the relapsing remitting disease is skipped and the patients show progression from the onset (primary progressive MS, PPMS). Evidence obtained so far indicate major differences between RRMS and progressive MS, but no essential differences between SPMS and PPMS, with the exception of a lower incidence in the global load of focal white matter lesions and in particular in the presence of classical active plaques in PPMS. We suggest that in MS patients two types of inflammation occur, which develop in parallel but partially independent from each other. The first is the focal bulk invasion of T- and B-lymphocytes with profound blood brain barrier leakage, which predominately affects the white matter, and which gives rise to classical active demyelinated plaques. The other type of inflammation is a slow accumulation of T-cells and B-cells in the absence of major blood brain barrier damage in the connective tissue spaces of the brain, such as the meninges and the large perivascular Virchow Robin spaces, where they may form aggregates or in most severe cases structures in part resembling tertiary lymph follicles. This type of inflammation is associated with the formation of subpial demyelinated lesions in the cerebral and cerebellar cortex, with slow expansion of pre-existing lesions in the white matter and with diffuse neurodegeneration in the normal appearing white or gray matter. The first type of inflammation dominates in acute and relapsing MS. The second type of inflammation is already present in early stages of MS, but gradually increases with disease duration and patient age. It is suggested that CD8<sup>+</sup> T-lymphocytes remain in the brain and spinal cord as tissue resident cells, which may focally propagate neuroinflammation, when they re-encounter their cognate antigen. B-lymphocytes may propagate demyelination and neurodegeneration, most likely by producing soluble neurotoxic factors. Whether lymphocytes within the brain tissue of MS lesions have also regulatory functions is presently unknown. Key open questions in MS research are the identification of the target antigen recognized by tissue resident CD8<sup>+</sup> T-cells and B-cells and the molecular nature of the soluble inflammatory mediators, which may trigger tissue damage.

Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression?

Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis

Systematic Understanding of Bioactive Lipids in Neuro-Immune Interactions: Lessons from an Animal Model of Multiple Sclerosis

Foamy microglia link oxylipins to disease progression in multiple sclerosis

Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction

Antioxidants and polyunsaturated fatty acids in multiple sclerosis

Blood-based targeted metabolipidomics reveals altered omega fatty acid-derived lipid mediators in relapsing-remitting multiple sclerosis patients

Lysophosphatidic acid receptor 1 influences disease severity in a mouse model of multiple sclerosis

Lysophosphatidic Acid Signaling Via LPA6: A Negative Modulator of Developmental Oligodendrocyte Maturation

Dietary fatty acids and susceptibility to multiple sclerosis

Protective Role of High-Density Lipoprotein in Multiple Sclerosis

Propionic Acid Impact on Multiple Sclerosis: Evidence and Challenges

A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis

Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis

Autophagy Modulation in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis

The neuropathobiology of multiple sclerosis

Lipid metabolism is dysregulated in endocrine glands upon autoimmune demyelination

Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis

Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics